Ilumya® (tildrakizumab-asmn)
for Psoriasis

Ilumya (tildrakizumab-asmn) injection is a humanized IgG1/k monoclonal antibody used for moderate-to-severe plaque psoriasis to reduce plaques, scales, and redness, making the skin clearer and less itchy. It works by blocking the IL-23 protein, which is involved in inflammatory and immune responses. Ilumya selectively binds to the p19 subunit of IL-23, blocking its interaction with the IL-23 receptor, reducing the release of inflammatory proteins, and improving plaque psoriasis symptoms.

Heart
Medication Guide Icon Medication Guide
TV Commercial Icon TV Commercial
Patient Website Icon Patient Website
Efficacy Data Icon Efficacy Data
New Articles Icon New Articles
Savings and Support Icon Savings and Support
Company MD Payments Icon Company MD Payments
Clinical Trials Icon Clinical Trials
Adverse Event Report Icon Adverse Event Report
Other top medicines used to treat Psoriasis